The anthem biosciences ipo gmp share price drew strong investor attention ahead of its listing on July 21, 2025. With a grey market premium (GMP) of ₹165–₹177, the stock was expected to deliver substantial listing gains. And it didn’t disappoint — the IPO was oversubscribed 67.4 times and listed at a 27% premium on both NSE and BSE.
Grey Market Premium (GMP) Before Listing
The anthem biosciences ipo gmp share price remained in the range of ₹165 to ₹177 during the days leading up to the IPO. This GMP translated to an expected listing gain of approximately 29–31% over the upper price band of ₹570, which helped fuel retail and institutional demand.
Listing Performance on NSE and BSE
Anthem Biosciences made an impressive debut on July 21:
- Issue Price: ₹570 per share
- NSE Listing Price: ₹723.05
- BSE Listing Price: ₹723.10
- Day’s High: ₹746.70 (BSE)
- Closing Price (NSE): ₹731.65
The strong listing gain confirmed investor optimism backed by robust grey market signals.
Post-Listing Share Price Momentum
The anthem biosciences share price held strong throughout the trading session. Analysts from Mehta Equities and Hensex Securities advised profit-booking at current levels for short-term investors. However, long-term investors were encouraged to hold the stock for targets between ₹900 to ₹1,000, considering the company’s robust fundamentals.
Company Overview and FY25 Financials
Anthem Biosciences is a Contract Research, Development, and Manufacturing Organisation (CRDMO) with integrated operations in both small molecules and biologics.
Key Financial Highlights:
- Revenue (FY25): ₹1,844 crore (30% YoY growth)
- EBITDA Margin: 37%
- ROCE: 20.8%
These strong numbers justify investor interest and support positive share price targets in the medium to long term.
Investment Pros & Cons
| Strengths | Risks |
|---|---|
| Strong debut and demand | High valuations post-listing |
| Integrated biotech capabilities | Regulatory dependencies and patent expiries |
| Solid growth in revenue and profitability | Rising competition in the biotech manufacturing space |
Expert Opinion and Target
Experts recommend a hold strategy for long-term gains, with potential upside up to ₹1,000. However, due to high initial valuations, cautious profit booking is advised near ₹730–₹750 levels.
Conclusion
The anthem biosciences ipo gmp share price proved to be an accurate indicator of market demand. The successful listing and future growth prospects make Anthem Biosciences a strong contender in the CRDMO sector.
FAQs
1. What was the GMP of Anthem Biosciences IPO?
It ranged from ₹165–₹177, indicating a 29–31% premium over the issue price.
2. At what price did the IPO list on NSE?
Anthem listed at ₹723.05 on NSE, a 27% gain over the issue price.
3. Is it a good time to buy Anthem Biosciences shares?
Short-term investors can book profits; long-term investors may hold for targets between ₹900–₹1,000.
4. What are the company’s financial strengths?
Revenue growth, high EBITDA margin, and strong return on capital.
5. What are the risks involved?
High valuation, regulatory risks, and biotech competition.
